BioSpace News Archive

TScan Therapeutics, Inc. announced that it has commenced an underwritten public offering of $125 million of shares of its voting common stock and, in lieu of voting common stock, to certain investors that so choose, pre-funded warrants to purchase shares of voting common stock.

Precision BioSciences, Inc. (Nasdaq: DTIL), an advanced gene editing company, today announced the anticipated return of three programs from Prevail Therapeutics Inc., a wholly owned subsidiary of Eli Lilly and Company.

HOOKIPA Pharma Inc. announced that the Compensation Committee of the Company’s Board of Directors approved the grant of non-statutory options to Mark Winderlich, who was appointed Chief Development Officer of the Company effective April 1, 2024, to purchase an aggregate of 250,000 shares of the Company’s Common Stock under HOOKIPA’s 2023 Inducement Plan.

INVO Bioscience, Inc. (Nasdaq: INVO) (“INVO” or the “Company”) today announced financial results for the fourth quarter and fiscal year ended December 31, 2023 and provided a business update.

Global RNA Analysis Transcriptomics Market is valued at US$ 11.26 Bn in 2023, and it is expected to reach US$ 42.43 Bn by 2031, with a CAGR of 18.30% during the forecast period of 2024-2031.

At this year’s Interphex, ACG Engineering, part of ACG - the world’s only integrated pharmaceutical solutions and manufacturing company - will be focusing on its cost-effective approach to taking generics to market.

OSE Immunotherapeutics SA (ISIN: FR0012127173; Mnemo: OSE) today announced that the Hart-Scott-Rodino waiting period has expired with respect to its global license with AbbVie to develop OSE-230, a monoclonal antibody designed to resolve chronic and severe inflammation, currently in the pre-clinical development stage.

The Board of Directors of the Kaiser Permanente Bernard J. Tyson School of Medicine announced the appointment of physician, educator, and women’s health expert John L. Dalrymple, MD, as the school’s new Dean and CEO after an extensive national search.

According to Vision Research Reports, the global plasmid DNA manufacturing market size was estimated at USD 1.83 billion in 2023

The U.S. Food and Drug Administration is providing an at-a-glance summary of news from around the agency.